MAIA enrolls first five patients in THIO-101 Part C expansion in Taiwan and Turkey

MAIA Biotechnology, Inc.

Presented trial-in-progress poster on ateganosine (THIO) plus ICI for advanced NSCLC at AACR-NCI-EORTC conference, Oct 22-26, 2025 in Boston.
Enrolled first five patients in Part C (expansion) of THIO-101 Phase 2 trial from Taiwan and Turkey.
Trial evaluates ateganosine (THIO) followed by cemiplimab in 3L NSCLC patients resistant to prior checkpoint inhibitor and chemo.
Screening ongoing in Europe and Asia with multi-continental sites; safety profile aligned with earlier parts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.